Conversion therapy strategy: A novel GPC3-targeted multimodal organic phototheranostics platform for mid-late-stage hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is typically diagnosed at intermediate to advanced stage, making surgical treatment unfeasible. Conversion therapy aims to reduce tumor stage, improve hepatic resection feasibility, and lower recurrence rates. Since traditional therapies are often accompanied by uncert...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006424005039 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841533242946093056 |
|---|---|
| author | Fan Wu Xin Kuang Sanlin Deng Shuo Qi Jian Xiong Bibo Zhao Chuanfu Li Senyou Tan Qiang Kang Hao Xiao Xiaofeng Tan Gui-long Wu Qinglai Yang Guodong Chen |
| author_facet | Fan Wu Xin Kuang Sanlin Deng Shuo Qi Jian Xiong Bibo Zhao Chuanfu Li Senyou Tan Qiang Kang Hao Xiao Xiaofeng Tan Gui-long Wu Qinglai Yang Guodong Chen |
| author_sort | Fan Wu |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is typically diagnosed at intermediate to advanced stage, making surgical treatment unfeasible. Conversion therapy aims to reduce tumor stage, improve hepatic resection feasibility, and lower recurrence rates. Since traditional therapies are often accompanied by uncertainty of efficacy, there is an urgent need to explore new treatment strategies. Near-infrared phototheranostics technology provides a new way for HCC diagnosis and treatment by its excellent optical properties. However, complex preparation and poor biocompatibility of phototheranostics probes limit clinical application. In this study, we developed a fluorescence/magnetic resonance dual-modality imaging (FLI/MRI) as well as photothermal/photodynamic therapy (PTT/PDT) GPC3-targeted multifunctional phototheranostics probe, IR820-GPC3-Gd NPs (IGD NPs), to improve the efficiency of conversion therapy for HCC. The IGD NPs were simply prepared with the IR820 as the core. Conjugating the HCC-specific targeting molecule GPC3 peptide and the MRI agent DOTA-Gd through click chemistry. IGD NPs target HCC cells through GPC3, releasing heat and reactive oxygen species (ROS) under noninvasive 808 nm laser irradiation to reduce tumor size and achieve downstaging. High-sensitivity FLI/MRI precisely delineates tumor boundaries, providing real-time surgical navigation and prognosis assessment. This novel probe offers a feasible and effective treatment option for advanced HCC. |
| format | Article |
| id | doaj-art-77f7448e87064839967002cd7f991920 |
| institution | Kabale University |
| issn | 2590-0064 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials Today Bio |
| spelling | doaj-art-77f7448e87064839967002cd7f9919202025-01-17T04:52:15ZengElsevierMaterials Today Bio2590-00642025-02-0130101442Conversion therapy strategy: A novel GPC3-targeted multimodal organic phototheranostics platform for mid-late-stage hepatocellular carcinomaFan Wu0Xin Kuang1Sanlin Deng2Shuo Qi3Jian Xiong4Bibo Zhao5Chuanfu Li6Senyou Tan7Qiang Kang8Hao Xiao9Xiaofeng Tan10Gui-long Wu11Qinglai Yang12Guodong Chen13Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Center for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Hunan Engineering Research Center for Early Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, ChinaDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Center for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Hunan Engineering Research Center for Early Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, ChinaDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Center for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Hunan Engineering Research Center for Early Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, ChinaDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Center for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, ChinaDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Center for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Hunan Engineering Research Center for Early Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, ChinaDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Center for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Hunan Engineering Research Center for Early Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, ChinaDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Center for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Hunan Engineering Research Center for Early Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, ChinaDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Center for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, ChinaCenter for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, ChinaCenter for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, ChinaCenter for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Corresponding author.Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Center for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Hunan Engineering Research Center for Early Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Corresponding author. Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Center for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Hunan Engineering Research Center for Early Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Corresponding author. Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, 28 West Changsheng Road, Hengyang, Hunan, 421001, China.Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Center for Molecular Imaging Probe Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Hunan Engineering Research Center for Early Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Department of General Surgery, Turpan City People's Hospital, Tulufan, 838000, China; Corresponding author. Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, 28 West Changsheng Road, Hengyang, Hunan, 421001, China.Hepatocellular carcinoma (HCC) is typically diagnosed at intermediate to advanced stage, making surgical treatment unfeasible. Conversion therapy aims to reduce tumor stage, improve hepatic resection feasibility, and lower recurrence rates. Since traditional therapies are often accompanied by uncertainty of efficacy, there is an urgent need to explore new treatment strategies. Near-infrared phototheranostics technology provides a new way for HCC diagnosis and treatment by its excellent optical properties. However, complex preparation and poor biocompatibility of phototheranostics probes limit clinical application. In this study, we developed a fluorescence/magnetic resonance dual-modality imaging (FLI/MRI) as well as photothermal/photodynamic therapy (PTT/PDT) GPC3-targeted multifunctional phototheranostics probe, IR820-GPC3-Gd NPs (IGD NPs), to improve the efficiency of conversion therapy for HCC. The IGD NPs were simply prepared with the IR820 as the core. Conjugating the HCC-specific targeting molecule GPC3 peptide and the MRI agent DOTA-Gd through click chemistry. IGD NPs target HCC cells through GPC3, releasing heat and reactive oxygen species (ROS) under noninvasive 808 nm laser irradiation to reduce tumor size and achieve downstaging. High-sensitivity FLI/MRI precisely delineates tumor boundaries, providing real-time surgical navigation and prognosis assessment. This novel probe offers a feasible and effective treatment option for advanced HCC.http://www.sciencedirect.com/science/article/pii/S2590006424005039Hepatocellular carcinomaGPC3Dual-modality imagingPhototheranosticsSurgical navigation |
| spellingShingle | Fan Wu Xin Kuang Sanlin Deng Shuo Qi Jian Xiong Bibo Zhao Chuanfu Li Senyou Tan Qiang Kang Hao Xiao Xiaofeng Tan Gui-long Wu Qinglai Yang Guodong Chen Conversion therapy strategy: A novel GPC3-targeted multimodal organic phototheranostics platform for mid-late-stage hepatocellular carcinoma Materials Today Bio Hepatocellular carcinoma GPC3 Dual-modality imaging Phototheranostics Surgical navigation |
| title | Conversion therapy strategy: A novel GPC3-targeted multimodal organic phototheranostics platform for mid-late-stage hepatocellular carcinoma |
| title_full | Conversion therapy strategy: A novel GPC3-targeted multimodal organic phototheranostics platform for mid-late-stage hepatocellular carcinoma |
| title_fullStr | Conversion therapy strategy: A novel GPC3-targeted multimodal organic phototheranostics platform for mid-late-stage hepatocellular carcinoma |
| title_full_unstemmed | Conversion therapy strategy: A novel GPC3-targeted multimodal organic phototheranostics platform for mid-late-stage hepatocellular carcinoma |
| title_short | Conversion therapy strategy: A novel GPC3-targeted multimodal organic phototheranostics platform for mid-late-stage hepatocellular carcinoma |
| title_sort | conversion therapy strategy a novel gpc3 targeted multimodal organic phototheranostics platform for mid late stage hepatocellular carcinoma |
| topic | Hepatocellular carcinoma GPC3 Dual-modality imaging Phototheranostics Surgical navigation |
| url | http://www.sciencedirect.com/science/article/pii/S2590006424005039 |
| work_keys_str_mv | AT fanwu conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma AT xinkuang conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma AT sanlindeng conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma AT shuoqi conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma AT jianxiong conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma AT bibozhao conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma AT chuanfuli conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma AT senyoutan conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma AT qiangkang conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma AT haoxiao conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma AT xiaofengtan conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma AT guilongwu conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma AT qinglaiyang conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma AT guodongchen conversiontherapystrategyanovelgpc3targetedmultimodalorganicphototheranosticsplatformformidlatestagehepatocellularcarcinoma |